ArticleCureus2026
An Unusual Presentation of Secondary Hemophagocytic Lymphohistiocytosis With Melena: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome characterized by excessive immune activation leading to multiorgan involvement. We present a case of an adult male with secondary HLH triggered by typhoid infection, manifesting with persistent fever, cytopenias, hepatosplenomegaly, and bone marrow hemophagocytosis. This report details the clinical presentation, laboratory findings, diagnostic challenges, management, and outcome, underscoring the importance of timely diagnosis and corticosteroid therapy. The clinical course and investigations fulfilled the established diagnostic criteria, illustrating the complexities of differentiating HLH from sepsis and other mimickers. Treatment with high-dose methylprednisolone led to clinical and hematological recovery. This case aligns with literature emphasizing early recognition and immunosuppressive therapy for improved prognosis in secondary HLH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.